Analysis on the Development Strategy of China’s Pharmaceutical
Enterprises under the Background of Volume Procurement

亚洲社会药学 ›› 2020, Vol. 15 ›› Issue (4): 193-197.

• • 下一篇

Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement

Chen Yuan, Chen Yuwen*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

出版日期:2020-12-20 发布日期:2020-12-14

Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement

Chen Yuan, Chen Yuwen*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

Online:2020-12-20 Published:2020-12-14
Contact: Chen Yuwen, male, professor. Major research area: pharmaceutical administration. Tel: 024-23986552, E-mail: cywwyc@163.com. E-mail:cywwyc@163.com

摘要/Abstract

摘要： Objective To provide reference for the development strategy of China’s enterprises under the current policy background of generic drug consistency evaluation and volume procurement. Methods China’s current policies on generic drugs and market environment were analyzed and the development paths of international top pharmaceutical enterprises were studied as well. Results and Conclusion There are four transformation and upgrading paths for China’s pharmaceutical enterprises. First, they should invest more in innovation to realize the globalization of new drugs. Second, overseas patented new drugs should be introduced actively. Third, they must focus on the research and development of high-end generic drugs. Lastly, the transformation from active pharmaceutical ingredients into pharmaceutic preparation should be carried out quickly. Under the background of volume procurement, the pharmaceutical market pattern will be completely changed. The research and development capability and patented drugs will become the core competitive advantages of enterprises.

关键词: volume procurement, generic drug, pharmaceutical enterprise

Abstract: Objective To provide reference for the development strategy of China’s enterprises under the current policy background of generic drug consistency evaluation and volume procurement. Methods China’s current policies on generic drugs and market environment were analyzed and the development paths of international top pharmaceutical enterprises were studied as well. Results and Conclusion There are four transformation and upgrading paths for China’s pharmaceutical enterprises. First, they should invest more in innovation to realize the globalization of new drugs. Second, overseas patented new drugs should be introduced actively. Third, they must focus on the research and development of high-end generic drugs. Lastly, the transformation from active pharmaceutical ingredients into pharmaceutic preparation should be carried out quickly. Under the background of volume procurement, the pharmaceutical market pattern will be completely changed. The research and development capability and patented drugs will become the core competitive advantages of enterprises.

Key words: volume procurement, generic drug, pharmaceutical enterprise

Chen Yuan, Chen Yuwen. Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement[J]. 亚洲社会药学, 2020, 15(4): 193-197.

Chen Yuan, Chen Yuwen. Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement[J]. Asian Journal of Social Pharmacy, 2020, 15(4): 193-197.

[1]	Wang Hongwei, Yang Yue. Research and Reference of the Authorized Generic Drug System in the US[J]. 亚洲社会药学, 2021, 16(1): 11-22.
[2]	Zhang Tianqi, Chen Yuwen. Research on the World’s Most Valuable Antihypertensive Drugs Based on Patent Analysis[J]. 亚洲社会药学, 2021, 16(1): 76-83.
[3]	Piao Huiling, Wei Xingchen, Wang Nan, Wang Xing, Zhou Yusheng, Dong Li. Current Effect of “4+7” Drug Centralized Volume Procurement and Suggestions for Future Improvement [J]. 亚洲社会药学, 2020, 15(4): 198-212.
[4]	Cui Yuepeng, Wang Zuoyu, Yuan Hongmei. Policy Suggestions on Procurement of Basic Infusion Against the Background of Volume Procurement [J]. 亚洲社会药学, 2020, 15(4): 213-222.
[5]	Tang Ying, Chen Yuwen. Risk Control Strategy in the Research and Development of Pediatric Drugs[J]. 亚洲社会药学, 2019, 14(3): 110-118.
[6]	Zheng Yongxia, Yang Yue. Discussion on Drug Procurement with Target Quantity in China and Its Problem[J]. 亚洲社会药学, 2019, 14(2): 59-65.
[7]	Huang Yufeng, Luo Suping, Yuan Hongmei. Research on Drug-Patent Linkage System under the New Situation[J]. 亚洲社会药学, 2019, 14(1): 7-14.
[8]	Mao Xiaofang, Qi Xiang, Zhou Fengxiang. Project Management of Generic Drug R&D and Registration in the United States[J]. 亚洲社会药学, 2018, 13(4): 113-123.
[9]	Lian Guiyu, Xu Ruguo. A Study of the Culture Construction of Pharmaceutical Enterprises in China[J]. 亚洲社会药学, 2018, 13(2): 64-68.
[10]	Fu Fei, Zhao Yinghuan. Social Responsibility of Pharmaceutical Enterprises and Consumer Responses: A Relationship Research[J]. 亚洲社会药学, 2018, 13(1): 27-32.
[11]	Liu yue, Sun Lihua. Introduction of Drug Re-evaluation in Foreign Countries and Its Enlightenment to China [J]. 亚洲社会药学, 2017, 12(1): 16-21.
[12]	. Brief Introduction of Generic Drug Registration System in 10 ASEAN Countries [J]. 亚洲社会药学, 2016, 11(2): 75-78.

亚洲社会药学

Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement

Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价